Smith D J, Akita H, King W F, Taubman M A
Department of Immunology, Forsyth Dental Center, Boston, Massachusetts 02115.
Infect Immun. 1994 Jun;62(6):2545-52. doi: 10.1128/iai.62.6.2545-2552.1994.
A novel glucan-binding protein (GBP) having an apparent molecular mass of 59 kDa (GBP59) has been purified from Streptococcus mutans SJ by a combination of affinity chromatography on alpha-1,6-linked glucan, gel filtration chromatography, and ion-exchange chromatography. GBP59 was distinct from the quantitatively predominant S. mutans GBP (GBP74) on the basis of size, elution position in a salt gradient, and antigenicity. Rat antisera to purified GBP59 and GBP74 did not cross-react. GBP59 is apparently immunogenic in humans, since immunoglobulin A (IgA) antibody in 20 of 24 adult parotid saliva samples was shown to react with GBP59 in an enzyme-linked immunosorbent assay. The glucan-binding activity of GBP59 was confirmed by anti-GBP59 immunogold labelling of Sephadex G-50 that had been preincubated with S. mutans culture supernatant. GBP59 could be detected in culture supernatants of all laboratory strains of S. mutans (e.g., Ingbritt), as well as all strains of S. mutans that had been recently isolated from young children. GBP59 was often the only component in protease inhibitor-containing 4-h S. mutans culture supernatants that reacted with human parotid salivary IgA antibody in Western blot (immunoblot) analyses. These studies suggest that GBP59 is a structurally and antigenically distinct S. mutans GBP that can elicit significant levels of salivary IgA antibody in humans.
通过对α-1,6-连接的葡聚糖进行亲和层析、凝胶过滤层析和离子交换层析相结合的方法,从变形链球菌SJ中纯化出了一种表观分子量为59 kDa的新型葡聚糖结合蛋白(GBP)(GBP59)。基于大小、盐梯度洗脱位置和抗原性,GBP59与定量上占主导地位的变形链球菌GBP(GBP74)不同。针对纯化后的GBP59和GBP74的大鼠抗血清不发生交叉反应。GBP59在人类中显然具有免疫原性,因为在24份成人腮腺唾液样本中的20份中,免疫球蛋白A(IgA)抗体在酶联免疫吸附试验中显示与GBP59发生反应。GBP59的葡聚糖结合活性通过对与变形链球菌培养上清液预孵育的葡聚糖凝胶G-50进行抗GBP59免疫金标记得到证实。在所有变形链球菌实验室菌株(如英布里特)以及最近从幼儿中分离出的所有变形链球菌菌株的培养上清液中都能检测到GBP59。在含有蛋白酶抑制剂的变形链球菌4小时培养上清液中,GBP59常常是在蛋白质印迹(免疫印迹)分析中与人腮腺唾液IgA抗体发生反应的唯一成分。这些研究表明,GBP59是一种在结构和抗原性上都不同的变形链球菌GBP,可以在人类中引发显著水平的唾液IgA抗体。